Inquiry Basket
CAS No.: 1938099-52-5
Cat No.: BADC-01491
4.5 
MP-PEG8-VA-PABC is a biomedical product used for targeted drug delivery in cancer treatment. With its polyethylene glycol (PEG) and maleimide functional groups, it efficiently conjugates to antibodies or therapeutic agents, enabling precise and controlled release at the tumor site. It shows potential in treating various types of cancers, including breast, lung, and prostate cancer.
Structure of 1938099-52-5
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MP-PEG8-VA-PABC, a multifunctional linker crucial in the advancement of cutting-edge drug delivery systems, boasts a myriad of applications.
Targeted Drug Delivery: MP-PEG8-VA-PABC plays a pivotal role in crafting targeted drug delivery vehicles that ferry therapeutics directly to ailing cells or tissues. By coupling this linker with drugs and targeting moieties, researchers adeptly enhance drug uptake by specific cells, especially cancer cells. This tailored strategy curtails off-target effects, amplifying the potency of treatments.
Prodrug Design: MP-PEG8-VA-PABC emerges as a crucial spacer and triggerable linker, governing the union between the active pharmaceutical ingredient (API) and the aiming entity. The strategic use of this linker permits controlled release of the API upon reaching the designated site, ensuring drug activation solely at the requisite location.
Bioconjugation: Within the domain of bioconjugation processes, MP-PEG8-VA-PABC acts as a linchpin, bridging biologically active molecules like peptides or antibodies to polymers or diverse compounds. This linkage begets bioconjugates endowed with heightened stability, solubility, and bioavailability, pivotal in crafting diagnostic tools and avant-garde therapeutic agents.
Complex Drug Formulation: Pioneering complex drug formulations, MP-PEG8-VA-PABC orchestrates the union of multiple therapeutic agents within a unified delivery framework. This innovation enables the concurrent dispensation of diverse drugs with synergistic impacts against ailments such as cancer and infectious diseases. By harnessing such formulations, researchers steer toward enhanced therapeutic efficacy and surmounting drug resistance.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01451 | MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT | 2378428-19-2 | |
| BADC-01517 | MP-PEG4-VK(Boc)G-OSu | 2378428-21-6 |
What is the primary function of the MP-PEG8-VA-PABC linker in ADC development?
The primary function of the MP-PEG8-VA-PABC linker is to provide a cleavable connection between the cytotoxic payload and the antibody. The valine-citrulline (VC) dipeptide is recognized and cleaved by lysosomal proteases, such as cathepsin B, after internalization of the ADC, thereby releasing the active drug in the target cell and minimizing systemic toxicity. The PEG8 spacer enhances solubility and reduces aggregation.
2/7/2018
Dear team, how does the PABC component contribute to the release mechanism of MP-PEG8-VA-PABC?
The p-aminobenzylcarbamate (PABC) self-immolative spacer in MP-PEG8-VA-PABC is crucial for the efficient release of the drug. Upon enzymatic cleavage of the valine-citrulline dipeptide, the PABC group undergoes a spontaneous 1,6-elimination reaction. This process liberates the drug with a free hydroxyl or amine group, ensuring the payload is released in its unmodified, active form within the lysosome.
28/11/2020
Could you kindly inform us what are the benefits of using a PEG8 spacer in the MP-PEG8-VA-PABC linker?
The PEG8 spacer in MP-PEG8-VA-PABC significantly improves the physicochemical properties of the ADC. The hydrophilic nature of PEG enhances the overall solubility of the conjugate, which can prevent aggregation. This improved solubility and reduced aggregation are critical for ensuring the stability and homogeneity of the final ADC product, which in turn impacts its efficacy and safety profile.
27/9/2016
Dear BOC Sciences, is MP-PEG8-VA-PABC suitable for site-specific conjugation?
Yes, the maleimide group (MP) at the end of MP-PEG8-VA-PABC is designed for specific conjugation to cysteine residues. This allows for site-specific conjugation strategies, such as those involving engineered antibodies with reduced cysteines. Site-specific conjugation yields a more homogeneous drug-to-antibody ratio (DAR), leading to a more consistent and predictable therapeutic profile compared to random conjugation methods.
20/9/2021
Good morning! Which analytical methods are recommended to verify MP-PEG8-VA-PABC for ADC applications?
MP-PEG8-VA-PABC identity and structural integrity are confirmed using NMR, HPLC, and mass spectrometry. These analyses ensure the linker maintains its reactive functional groups and provides traceable quality documentation for consistent performance in antibody-drug conjugation processes.
5/10/2016
— Dr. Sarah Collins, Protein Chemist (USA)
MP-PEG8-VA-PABC linker improved solubility and flexibility for conjugation reactions, streamlining ADC development.
27/9/2016
— Prof. Markus Fischer, Medicinal Chemist (Germany)
The long PEG chain of MP-PEG8-VA-PABC minimized steric hindrance and enhanced payload accessibility.
5/10/2016
— Dr. Claudia Rossi, ADC Scientist (Italy)
BOC Sciences delivered MP-PEG8-VA-PABC with excellent purity and reproducibility across batches.
20/9/2021
— Ms. Emily Parker, R&D Manager (UK)
MP-PEG8-VA-PABC allowed smooth aqueous conjugations and reduced aggregation.
2/7/2018
— Dr. Henrik Larsen, Bioconjugation Specialist (Denmark)
The linker’s design improved workflow efficiency and conjugation yield. Very satisfied.
— Mr. Felix Johnson, Senior Scientist (France)
High-quality PEG linker that simplified ADC development. Excellent support from BOC Sciences.
28/11/2020
MP-PEG8-VA-PABC
Required fields are marked with *
MP-PEG8-VA-PABC
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
